Eledon Pharmaceuticals Inc
NASDAQ:ELDN

Watchlist Manager
Eledon Pharmaceuticals Inc Logo
Eledon Pharmaceuticals Inc
NASDAQ:ELDN
Watchlist
Price: 1.66 USD 0.61% Market Closed
Market Cap: 124.5m USD

Net Margin
Eledon Pharmaceuticals Inc

0%
Current
0%
Average
-6.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-10.2m
/
Revenue
0

Net Margin Across Competitors

No Stocks Found

Eledon Pharmaceuticals Inc
Glance View

Market Cap
124.5m USD
Industry
Biotechnology

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The company is headquartered in Irvine, California and currently employs 12 full-time employees. The company went IPO on 2014-09-17. The firm is focused on developing targeted medicines for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with amyotrophic lateral sclerosis (ALS). Its lead compound in development is AT-1501, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand (CD40L, also called CD154). AT-1501 is engineered to improve both safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches. Blocking CD40L inhibits both CD40 and CD11 costimulatory signaling pathways with the potential for better efficacy. The company is focused on developing AT-1501 in up to four indications: ALS, prevention of kidney allograft rejection, prevention of islet cell allograft rejection, and IgA Nephropathy (IgAN). The company has completed a Phase Ia/Ib single ascending dose trial in volunteers and people with amyotrophic lateral sclerosis (ALS).

ELDN Intrinsic Value
1.24 USD
Overvaluation 25%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
0%
=
Net Income
-10.2m
/
Revenue
0
What is the Net Margin of Eledon Pharmaceuticals Inc?

Based on Eledon Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of 0%.

Back to Top